

OCTOBER 2024

Vielight News

Accelerating photobiomodulation.

RX PLUS

Medical Device
License Expansion

The Vielight RX Plus is intended to accelerate the recovery of upper respiratory symptoms in viral infections, such as COVID-19.



VIELIGHT



Newsletter Highlights

Viral Recovery
Clinical Trial Published

Vielight Research
Ecosystem

Share your
Experience!

VIELIGHT

VIRAL RECOVERY MAJOR CLINICAL TRIAL RESULTS


READ MORE >>

The landmark clinical trial results of the RX-Plus (**X-Plus 4** medical device equivalent) on upper respiratory viral recovery, tested on 294 participants during the COVID-19 pandemic, are **published**.

Based on the results, treatment patients with 0–7 days of symptoms experienced significantly faster recovery than those receiving standard care alone.

For the full study population, the RX-Plus showed statistically significant improvements in recovery times for symptoms such as sinus pain, chest congestion, body aches, mental clarity, ear discomfort, sinus drainage, headache, cough with sputum, and sneezing.

Certified by Health Canada, the RX-Plus is a groundbreaking device for accelerating recovery from viral upper respiratory symptoms, including COVID-19, and remains the only photobiomodulation device backed by large-scale clinical data for upper respiratory recovery.



VIELIGHT RESEARCH ECOSYSTEM

READ MORE



At Vielight, our researchers are committed to advancing photobiomodulation research to enhance human health, in partnership with leading researchers worldwide.

Our patented Vie-LED technology, which delivers high irradiance with minimal heat, is featured in the largest number of published studies and active clinical trials globally by a wide margin.

Discover more in our [detailed document](#) on published and ongoing research.



SHARE YOUR EXPERIENCE

Do you have an experience you would like to share with Vielight technology?

Contact us if you're interested in sharing your story!

Email: social@vielight.com